Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk2816126. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 known ✓ | Q15910 | 17/20 | 1.00 |
| ▸ | EZH1 | Q92800 | 6/20 | 1.00 |
| ▸ | EED | O75530 | 3/20 | 1.00 |
| ▸ | SUZ12 | Q15022 | 3/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.62 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.62 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk2816126 SCHEMBL2593705 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| Gsk2816126 SCHEMBL29352969 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| Gsk2816126 SCHEMBL12180401 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL14933215 | 0.94 | EZH2 (0.90) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19033201 | 0.94 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL29308159 | 0.94 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL18768926 | 0.94 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2594075 | 0.94 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL14726866 | 0.93 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL14726845 | 0.93 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | claimed |
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | claimed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-20150313887-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | claimed |
| US-8975291-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-03-10 | — | — | US | claimed |
| US-20130345200-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | claimed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | claimed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | claimed |
| US-20220218714-A1 | METHOD OF TREATING CANCER | Epizyme, Inc. | 2022-07-14 | — | — | US | disclosed |
| US-10946024-B2 | Method for treating cancer | Epizyme, Inc. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200330472-A1 | METHOD OF TREATING CANCER | Epizyme, Inc. | 2020-10-22 | — | — | US | disclosed |
| EP-3659606-A1 | METHODS OF TREATING CANCER | Epizyme, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20190240230-A1 | METHOD OF TREATING CANCER | Epizyme, Inc. | 2019-08-08 | — | — | US | disclosed |
| US-10369155-B2 | Method for treating cancer | Epizyme, Inc. (US) | 2019-08-06 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946024-B2 | Method for treating cancer | EZH2, BMI1, EZH1 | EZH2 1/4885EZH1 3/4885EED 10/4885 |
| US-20190240230-A1 | METHOD OF TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885EZH1 3/4885EED 22/4885 |
| US-20220218714-A1 | METHOD OF TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885EZH1 3/4885EED 35/4885 |
| US-20200330472-A1 | METHOD OF TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885EZH1 3/4885EED 22/4885 |
| US-10369155-B2 | Method for treating cancer | EZH2, BMI1, EZH1 | EZH2 1/4885EZH1 3/4885EED 10/4885 |
| US-20150313887-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 257/4885EZH1 669/4885EED 3322/4885 |
| US-20130345200-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 257/4885EZH1 669/4885EED 3322/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 239/4885EZH1 677/4885EED 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.